Latest Conference Articles

April 13th 2019, 9:37pm

European Lung Cancer Congress

Tony Mok, MD, discusses the KEYNOTE-042 trial and the implications of its findings, and sheds light on the evolving role of immunotherapy in non–small cell lung cancer.

April 13th 2019, 9:28pm

European Lung Cancer Congress

No overall survival advantage was obtained from maintenance therapy comprising nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) over placebo in patients with extensive-stage small cell lung cancer.

April 12th 2019, 10:45pm

European Lung Cancer Congress

Suresh S. Ramalingam, MD, describes findings with osimertinib, and discusses the emerging body of data exploring primary and acquired resistance mechanisms to the third-generation agent.

April 12th 2019, 10:10pm

European Lung Cancer Congress

Final results from 2 phase I expansion cohorts of frontline osimertinib (Tagrisso) presented at the 2019 European Lung Cancer Congress confirmed the efficacy of the third-generation TKI in patients with EGFR-positive non­–small cell lung cancer.

April 12th 2019, 9:02pm

European Lung Cancer Congress

Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses the rationale for the IMpower150 study.

April 12th 2019, 8:51pm

European Lung Cancer Congress

Luis G. Paz-Ares, MD, PhD, chief physician at the Hospital Universitario Doce De Octubre, discusses an integrated analysis of patients with NTRK fusion–positive non–small-cell lung cancer enrolled in the STARTRK-2, STARTRK-1, and ALKA-372-001 trials, which evaluated the safety and efficacy of entrectinib in patients with solid tumors.

April 12th 2019, 12:19am

European Lung Cancer Congress

Patients with ROS1-positive non–small cell lung cancer showed high response rates and durable responses following treatment with entrectinib.

April 11th 2019, 9:07pm

European Lung Cancer Congress

Patient reported outcomes according to PD-L1 expression did not show clinically meaningful differences in quality of life with either durvalumab or placebo in patients with stage III non–small cell lung cancer, according to a retrospective analysis of the phase III PACIFIC study.

April 11th 2019, 8:53pm

European Lung Cancer Congress

The initial overall survival analysis of the phase III MYSTIC trial of first-line durvalumab (Imfinzi) alone or in combination with tremelimumab compared with platinum-based chemotherapy in patients with metastatic non–small cell lung cancer, may have been confounded by high rates of post-study immunotherapy given in the control arm.

April 11th 2019, 8:21pm

European Lung Cancer Congress

Antonio Passaro, MD, PhD, of the Division of Thoracic Oncology, European Institute of Oncology, discusses a study that sought to determine the factors that have an impact on 5-year survival among patients treated for metastatic non–small cell lung cancer using ALK TKIs.

April 11th 2019, 6:37pm

European Lung Cancer Congress

Larotrectinib showcased an overall response rate of 71% in patients with non–small cell lung cancer harboring NTRK gene fusions.

April 11th 2019, 6:31pm

European Lung Cancer Congress

Leora Horn, MD, MSc, associate professor of cancer research, Vanderbilt University Medical Center, discusses the use of circulating tumor DNA analysis as a means to monitor response to, as well as resistance to, ensartinib in patients with ALK–positive non–small cell lung cancer.

April 3rd 2019, 12:45am

AACR Annual Meeting

Sandip Patel, MD, associate professor of medicine at the University of California San Diego School of Medicine, discusses the benefit of the immune checkpoint inhibitor combination of ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with rare, high-grade neuroendocrine tumors.

April 2nd 2019, 11:46pm

AACR Annual Meeting

Primary tumor surgery for patients with stage IV HER2-positive breast cancer is associated with an improvement in overall survival, according to results of a retrospective cohort review presented at the 2019 AACR Annual Meeting.

April 2nd 2019, 11:42pm

AACR Annual Meeting

Lecia V. Sequist, MD, MPH, thoracic medical oncologist and director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital Cancer Center, discusses the rationale for the TATTON trial in non–small cell lung cancer (NSCLC).

April 2nd 2019, 10:14pm

AACR Annual Meeting

A third of patients with advanced TRK fusion tumors had objective responses to the second-generation TRK inhibitor LOXO-195 after failure of initial anti-TRK therapy.

April 2nd 2019, 9:15pm

AACR Annual Meeting

Maintenance therapy with rucaparib maintained disease control and was well tolerated in patients with platinum-sensitive, advanced BRCA1/2- or PALB2-mutant pancreatic cancer, according to preliminary interim findings of a single-arm, phase II trial.

April 2nd 2019, 8:52pm

AACR Annual Meeting

Tumor mutational burden identified patients who obtained a survival benefit with the PD-L1 inhibitor durvalumab, as initial therapy versus chemotherapy for advanced non–small cell lung cancer, even though the primary analysis of the randomized trial showed no difference between treatment groups, according to a new analysis.

April 2nd 2019, 4:20am

AACR Annual Meeting

Pembrolizumab (Keytruda) demonstrated promising antitumor activity with durable responses in patients with pretreated advanced small cell lung cancer.

April 2nd 2019, 3:36am

AACR Annual Meeting

Eric J. Jacobs, PhD, cancer epidemiologist and strategic director of pharmacoepidemiology, American Cancer Society, discusses results from a prospective cohort study examining the association between BMI and pancreatic cancer mortality.